Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 8/20 | 0.64 |
| ▸ | CA1 known ✓ | P00915 | 7/20 | 0.64 |
| ▸ | CA12 known ✓ | O43570 | 7/20 | 0.64 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.64 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL28715890 | 0.95 | CA1 (0.64) | CA2CA1CA12CA9CA4 | |
| SCHEMBL4640918 | 0.80 | ALDH1A1 (0.79) | CA2CA1CA12CA9CA4 | |
| SCHEMBL19953365 | 0.79 | LMNA (0.55) | CA2CA1CA12CA9CA4 | |
| SCHEMBL1144444 | 0.78 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| Hydrochloric Acid SCHEMBL5142727 | 0.78 | ALDH1A1 (0.76) | CA2CA1CA12CA9CA4 | |
| Hydrochloric Acid SCHEMBL981171 | 0.76 | CA2 (0.95) | CA2CA1CA12CA9CA4 | |
| SCHEMBL486575 | 0.76 | CA12 (0.64) | CA2CA1CA12CA9CA4 | |
| SCHEMBL9175152 | 0.76 | CA12 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL34520 | 0.76 | CA1 (0.64) | CA2CA1CA12CA9CA4 | |
| Hydrazine SCHEMBL7570110 | 0.76 | CA2 (0.95) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213721-B | Rubber composition and preparation method thereof | 青岛双星轮胎工业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114213721-A | Rubber composition and preparation method thereof | 青岛双星轮胎工业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10478512-B2 | Charge-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10201621-B2 | Charge-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180177896-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2393420-B1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170290927-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-10-12 | — | — | US | disclosed |
| US-9687567-B2 | Charged-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150209451-A1 | CHARGED-BALANCED IMAGING AGENTS | BETH ISRAEL HOSPITAL (US) | 2015-07-30 | — | — | US | disclosed |
| US-9023611-B2 | Charged-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120028291-A1 | CHARGED-BALANCED IMAGING AGENTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2393420-A1 | CHARGE-BALANCED IMAGING AGENTS | Beth Israel Deaconess Medical Center, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091243-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-4017509-A | OXIDATION OF CORRESPONDING ALCOHOL | MITSUI TOATSU CHEMICALS, INCORPORATED (JA) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201621-B2 | Charge-balanced imaging agents | PHOSPHO1, ACTB, CYTH3 | CA2 77/4885CA1 110/4885CA12 52/4885 |
| US-10478512-B2 | Charge-balanced imaging agents | PHOSPHO1, ACTB, CYTH3 | CA2 77/4885CA1 110/4885CA12 52/4885 |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | ATP6V1B1, SLC8B1, PHOSPHO1 | CA2 305/4885CA1 728/4885CA12 104/4885 |
| US-20150209451-A1 | CHARGED-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, ARFGAP1 | CA2 116/4885CA1 56/4885CA12 25/4885 |
| US-20120028291-A1 | CHARGED-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, ARFGAP1 | CA2 116/4885CA1 56/4885CA12 25/4885 |
| US-20170290927-A1 | CHARGE-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, CYTH3 | CA2 77/4885CA1 110/4885CA12 52/4885 |
| US-20180177896-A1 | CHARGE-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, CYTH3 | CA2 77/4885CA1 110/4885CA12 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.